公司资料
Eli Lilly 股价、新闻与催化剂
- 股票代码:
- LLY
- 交易所:
- NYSE
- 行业:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- 所在地:
- United States
股票表现
1,149.85 USD (-0.62%)
收盘价
最后更新: 2026年10月1日
949B USD
市值
股价为何变动
截至 2026年10月1日，LLY 下跌 0.62%，收于 $1149.85。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Global Research-Based Medicines Company
Eli Lilly is a global pharmaceutical company that develops and commercializes medicines using capabilities in biotechnology, medicinal chemistry, and genetic medicine. Its research and commercial portfolio is concentrated in diabetes and obesity, neuroscience, immunology, and oncology, with external acquisitions increasingly adding genetic medicine, infectious disease, and neuropsychiatry programs.
Diabetes and Obesity Leadership
Lilly's largest franchise is built around incretin medicines for metabolic disease. Mounjaro is marketed for type 2 diabetes and Zepbound for chronic weight management and related complications, while oral GLP-1 candidate orforglipron, branded Foundayo in advance of potential commercialization, is intended to broaden access to incretin therapy without injection or food-and-water dosing restrictions. Retatrutide, a once-weekly GIP, GLP-1, and glucagon receptor agonist, is being developed for obesity and complications including obstructive sleep apnea and knee osteoarthritis pain.
Neuroscience and Immunology
The neuroscience portfolio includes Kisunla for early symptomatic Alzheimer's disease and acquired programs addressing sleep-wake disorders and treatment-resistant depression. In immunology, Lilly markets Ebglyss for atopic dermatitis and Omvoh for inflammatory bowel disease, supported by research across chronic inflammatory and autoimmune conditions.
Oncology Portfolio
Lilly's oncology business combines targeted small molecules, biologics, and biomarker-driven development. Commercial products include Jaypirca for B-cell malignancies, Retevmo for RET-driven cancers, and Inluriyo for estrogen receptor-positive breast cancer, while the pipeline includes olomorasib in KRAS G12C-mutated tumors and additional programs added through the acquisition of Ajax Therapeutics.
Genetic Medicine and External Innovation
The company is expanding beyond its traditional discovery platforms through acquisitions and partnerships. Orna Therapeutics and Kelonia Therapeutics add circular RNA and in vivo genetic medicine capabilities, Centessa adds sleep-wake assets, and additional transactions are establishing infectious disease and neuropsychiatry portfolios. VERVE-102, an in vivo PCSK9 base-editing program, illustrates Lilly's interest in potentially one-time genetic treatments for common cardiometabolic disease.
未来催化剂
- U.S. FDA submission of a Biologics License Application for retatrutide in obesity in the first quarter of 2027, supported by the completed Phase 3 registration package covering obesity, obstructive sleep apnea, and knee osteoarthritis pain.
- FDA review and potential decision on the submitted U.S. application for orforglipron in type 2 diabetes.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。